

Human CellExp™ 4-1BB / TNFRSF9, Fc Tag, Human Recombinant

CATALOG NO: P1306-10 10 µg
P1306-50 50 µg

ALTERNATE NAMES: TNFRSF9, 4-1BB, CD137, CDw137, ILA

SOURCE: HEK 293 cells (Gln 25 - Gln 186)

PURITY: > 95% by SDS – PAGE

MOL. WEIGHT: The protein has a calculated MW of 43.3 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

ENDOTOXIN LEVEL: < 1.0 EU per 1µg of protein (determined by LAL method)

FORM: Lyophilized

FORMULATION: Lyophilized from 0.22 µm filtered solution in 50 mM Tris, 100 mM Glycine, pH 7.5. Normally trehalose is added as protectant before lyophilization.

STORAGE CONDITIONS: Store at -20°C. After reconstitution, aliquot and store at -80°C and use within 3 months. Avoid repeated freezing and thawing cycles.

RECONSTITUTION: Centrifuge the vial prior to opening. Reconstitute in sterile deionized water to a concentration of 50 µg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% (W/V) HSA or BSA) is recommended for further dilution and long term storage. Do not vortex.

DESCRIPTION: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

SPECIFIC ACTIVITY:

Immobilized Human 4-1BB, Fc Tag at 0.1 µg/mL (100 µL/well) can bind Biotinylated Human 4-1BB Ligand, Fc Tag, Avi Tag with a linear range of 0.4-13 ng/mL




Fig. A. Human 4-1BB, Fc Tag on SDS-PAGE under reducing (R) condition

Fig. B. Immobilized Human 4-1BB, Fc Tag at 0.1 µg/mL (100 µL/well) can bind Biotinylated Human 4-1BB Ligand, Fc Tag, Avi Tag with a linear range of 0.4-13 ng/mL

RELATED PRODUCT:

- Human CellExp™ 4-1BB / TNFRSF9, Human recombinant (**Cat. No. 9227**)
- Human CellExp™ 4-1BB Ligand/TNFSF9, Human recombinant (**Cat. No. 9240**)
- 4-1BBR, human recombinant (**Cat. No. 4370**)
- 4-1BBL, human recombinant (**Cat. No. 4369**)

FOR RESEARCH USE ONLY! Not to be used on humans.